Conv. Plasma
Nigella Sativa

All phthalocyanine studies
Meta analysis
study COVID-19 treatment researchPhthalocyaninePhthalocyanine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial

Colado Simão et al., German Medical Science GMS Publishing House, doi:10.3205/000321
Jun 2023  
  Source   PDF   All Studies   Meta AnalysisMeta
Ct improvement, day 3 51% Improvement Relative Risk Ct improvement, day 3 (b) 38% Ct improvement, day 1 72% Ct improvement, day 1 (b) 68% Phthalocyanine  Colado Simão et al.  LATE TREATMENT  DB RCT Is late treatment with phthalocyanine beneficial for COVID-19? Double-blind RCT 75 patients in Brazil (November 2020 - February 2021) Improved viral clearance with phthalocyanine (p=0.0075) Colado Simão et al., German Medical Sc.., Jun 2023 Favorsphthalocyanine Favorscontrol 0 0.5 1 1.5 2+
31st treatment shown to reduce risk in December 2021
*, now with p = 0.00019 from 4 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments.
RCT 75 patients in Brazil, showing significantly lower viral load with phthalocyanine mouthwash and nasal spray. The combination was more effective than mouthwash alone.
relative Ct improvement, 50.7% better, RR 0.49, p = 0.008, treatment mean 11.21 (±4.35) n=15, control mean 5.53 (±6.28) n=15, mouthwash and nasal spray, day 3.
relative Ct improvement, 38.3% better, RR 0.62, p = 0.08, treatment mean 8.96 (±4.01) n=16, control mean 5.53 (±6.28) n=15, mouthwash only, day 3.
relative Ct improvement, 71.7% better, RR 0.28, p = 0.06, treatment mean 5.48 (±5.33) n=15, control mean 1.55 (±5.54) n=15, mouthwash and nasal spray, day 1.
relative Ct improvement, 68.4% better, RR 0.32, p = 0.08, treatment mean 4.91 (±4.89) n=16, control mean 1.55 (±5.54) n=15, mouthwash only, day 1.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Colado Simão et al., 23 Jun 2023, Double Blind Randomized Controlled Trial, placebo-controlled, Brazil, peer-reviewed, 13 authors, study period 1 November, 2020 - 1 February, 2021, average treatment delay 5.4 days.
This PaperPhthalocyanineAll
Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in patients with COVID-19: a randomized controlled trial Wirkung von oralen und nasalen antiseptischen Phthalocyanin-Lösungen auf die Infektiosität von SARS-CoV-2 bei Patienten mit COVID-19: eine randomisierte kontrollierte Studie
Andréa Name, Colado Simão, Nicole Perugini Stadtlober, Alesandra Audrey, Garcia Stinghen, Lonni, Mara Luiza, Venâncio, Guilherme Lerner, Pedro Luis Candido De Souza Cassela, Thais Mastellini Sanches, Maria De, Fátima Oliveira, Hirth Ruiz, Marcell Alysson, Batisti Lozovoy, Zuleica Naomi Tano, Bernardo Da Fonseca Orcina, Fabiano Vieira, Prof. Dr Paulo Sérgio, Silva Santos, Alameda Doutor, Octavio Pinheiro Brisolla
Background: In individuals with coronavirus disease (COVID-19), the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load (VL) plays an important role in infectivity.
Ethics statement The
Burton, Clarkson, Goulao, Glenny, Mcbain et al., Use of antimicrobial mouthwashes (gargling) and nasal sprays by healthcare workers to protect them when treating patients with suspected or confirmed COVID-19 infection, Cochrane Database Syst Rev, doi:10.1002/14651858.CD013626.pub2
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Euro Surveill, doi:10.2807/1560-7917.ES.2020.25.3.2000045
Da Fonseca Orcina, Vilhena, De Oliveira, Da, Alves et al., A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series, Clin Cosmet Investig Dent, doi:10.2147/CCIDE.S295423
Da, Santos, Da Fonseca Orcina, Da, Alves et al., A Recommendation of PHTALOX® Mouthwash for Preventing Infection and Progression of COVID-19, Acta Scient Dent Sci, doi:10.31080/ASDS.2020.04.0991
Da, Santos, Da Fonseca Orcina, Machado, Vilhena et al., Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial, Sci Rep, doi:10.1038/s41598-021-99013-5
Davidson, Tapson, Irwin, French, Elliott et al., Pharyngeal Antisepsis to Reduce COVID-19 Pneumonia, Am J Med, doi:10.1016/j.amjmed.2020.12.001
Fajnzylber, Regan, Coxen, Corry, Wong et al., SARS-CoV-2 viral load is associated with increased disease severity and mortality, Nat Commun, doi:10.1038/s41467-020-19057-5
Fini, Oral saliva and COVID-19. Oral Oncol, doi:10.1016/j.oraloncology.2020.104821
Health, Understanding cycle threshold (Ct) in SARS-CoV-2 RT-PCR: a guide for health protection teams
Herrera, Serrano, Roldán, Sanz, Is the oral cavity relevant in SARS-CoV-2 pandemic?, Clin Oral Investig, doi:10.1007/s00784-020-03413-2
Huang, Pérez, Kato, Mikami, Okuda et al., NIH COVID-19 Autopsy Consortium; HCA Oral and Craniofacial Biological Network. SARS-CoV-2 infection of the oral cavity and saliva, Nat Med, doi:10.1038/s41591-021-01296-8
Jaafar, Aherfi, Wurtz, Grimaldier, Hoang et al., Correlation Between 3,790 Quantitative Polymerase Chain Reaction-Positives Samples and Positive Cell Cultures, Including 1,941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates, Clin Infect Dis, doi:10.1093/cid/ciaa1491
Jefferson, Spencer, Brassey, Heneghan, Viral Cultures for Coronavirus Disease 2019 Infectivity Assessment: A Systematic Review, Clin Infect Dis, doi:10.1093/cid/ciaa1764
Magleby, Westblade, Trzebucki, Simon, Rajan et al., Impact of Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients With Coronavirus Disease, Clin Infect Dis, doi:10.1093/cid/ciaa851
Matson, Yinda, Seifert, Bushmaker, Fischer et al., Effect of Environmental Conditions on SARS-CoV-2 Stability in Human Nasal Mucus and Sputum. Emerg Infect Dis, doi:10.3201/eid2609.202267
Orcina, Santos, Oral manifestation COVID-19 and the rapid resolution of symptoms post-phtalox treatment: A case series, Int. J. Odontostomat, doi:10.4067/S0718-381X2021000100067
Rao, Manissero, Steele, Pareja, A Systematic Review of the Clinical Utility of Cycle Threshold Values in the Context of COVID-19, doi:10.1007/s40121-020-00324-3
Santos, Da Fonseca Orcina, Reia, Ribeiro, Grotto et al., Virucidal Activity of the Antiseptic Mouthwash and Dental Gel Containing Anionic Phthalocyanine Derivative: In vitro Study, Clin Cosmet Investig Dent, doi:10.2147/CCIDE.S315419
Stathis, Victoria, Loomis, Nguyen, Eggers et al., Review of the use of nasal and oral antiseptics during a global pandemic, Future Microbiol, doi:10.2217/fmb-2020-0286
{ 'type': 'article-journal', 'id': '', 'categories': [ 'COVID-19', 'SARS-CoV-2 infection', 'infectivity', 'phthalocyanine', 'mouthwashes', 'COVID-19', 'SARS-CoV-2-Infektion', 'Infektiosität', 'Phthalocyanin', 'Mundspülungen', 'Medicine and health'], 'language': 'en', 'author': [ {'family': 'Colado Simão', 'given': 'Andréa Name'}, {'family': 'Perugini Stadtlober', 'given': 'Nicole'}, {'family': 'Stinghen Garcia Lonni', 'given': 'Audrey Alesandra'}, {'family': 'Venâncio', 'given': 'Luiza Mara'}, {'family': 'Lerner Trigo', 'given': 'Guilherme'}, {'family': 'de Souza Cassela', 'given': 'Pedro Luis Candido'}, {'family': 'Mastellini Sanches Silva', 'given': 'Thais'}, {'family': 'De Fátima Oliveira Hirth Ruiz', 'given': 'Maria'}, {'family': 'Batisti Lozovoy', 'given': 'Marcell Alysson'}, {'family': 'Tano', 'given': 'Zuleica Naomi'}, {'family': 'da Fonseca Orcina', 'given': 'Bernardo'}, {'family': 'Vieira Vilhena', 'given': 'Fabiano'}, {'family': 'da Silva Santos', 'given': 'Paulo Sérgio'}], 'issued': {'date-parts': [[2023, 6, 23]]}, 'abstract': 'Background: In individuals with coronavirus disease (COVID-19), the severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2) viral load (VL) plays an important role in infectivity. ' 'Objectives: This study aimed to evaluate the reduction in the VL and infectivity induced by ' 'phthalocyanine mouthwash and nasal spray in patients with COVID-19. Methods: Patients with ' 'mild COVID-19 were recruited to participate in a triple-blinded randomized controlled trial. ' 'Participants were assigned to one of three groups: Group 1, non-active mouthwash and saline ' 'nasal spray (SNS); Group 2, phthalocyanine mouthwash and SNS; and Group 3 phthalocyanine ' 'mouthwash and phthalocyanine nasal spray. VL was assessed in nasopharyngeal and oropharyngeal ' 'swabs collected at the time of clinical diagnosis at baseline as well as 24 and 72 hours ' 'after starting the rinsing protocols. Findings: Forty-six participants were included in the ' 'analysis: 15, 16, and 15 in Groups 1, 2, and 3, respectively. After 72 hours, the reduction ' 'in VL was significantly higher in Group 3 (mean cycle threshold (Ct) decrease: 11.21) than in ' 'Group 1 (mean Ct decrease: 5.53). Additionally, only the mean VL in Group 3 was reduced to a ' 'non-contagious level after 72 hours. Main conclusions: Use of phthalocyanine mouthwash and ' 'nasal spray is effective at reducing SARS-CoV-2 infectivity.', 'DOI': '10.3205/000321', 'publisher': 'German Medical Science GMS Publishing House', 'title': 'Effect of phthalocyanine oral and nasal antiseptic solutions on the infectivity of SARS-CoV-2 in ' 'patients with COVID-19: a randomized controlled trial', 'URL': '', 'copyright': 'Creative Commons Attribution 4.0 International'}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop